Verition Fund Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$455K Sell
31,200
-4,963
-14% -$88K ﹤0.01% 1659
2026
Q1
$686K Sell
36,163
-192,827
-84% -$3.12M ﹤0.01% 1473
2025
Q4
$4.01M Buy
228,990
+63,388
+38% +$1.19M 0.02% 1045
2025
Q3
$3.42M Sell
165,602
-16,381
-9% -$397K 0.01% 1532
2025
Q2
$3.87M Buy
+181,983
New +$4.15M 0.02% 1375
2025
Q1
Sell
-43,561
Closed -$777K 3676
2024
Q4
$777K Buy
43,561
+24,884
+133% +$482K ﹤0.01% 2200
2024
Q3
$409K Buy
+18,677
New +$261K ﹤0.01% 2443
2023
Q2
Sell
-116,022
Closed -$203K 2516
2023
Q1
$203K Buy
+116,022
New +$316K ﹤0.01% 1759

Other funds holding SMMT

Verition Fund Management's SMMT Position: Q2 2026 in Review

Verition Fund Management reduced its Summit Therapeutics (SMMT) stake by 14% in Q2 2026, selling an estimated $88K and leaving 31,200 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Verition Fund Management first reported a position in SMMT in Q1 2023 and has held it in 8 quarters since. The position peaked at $4.01M in Q4 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Verition Fund Management held 31,200 shares of Summit Therapeutics worth $455K as of Q2 2026.
  • Verition Fund Management sold 4,963 Summit Therapeutics shares in Q2 2026, an estimated $88K.
  • Summit Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1659 holding.
  • Verition Fund Management first reported a position in Summit Therapeutics in Q1 2023 and has held it in 8 quarters since.
  • Verition Fund Management's Summit Therapeutics position peaked at $4.01M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.